|Bid||9.40 x 900|
|Ask||9.70 x 1200|
|Day's Range||9.04 - 9.50|
|52 Week Range||7.45 - 22.40|
|Beta (5Y Monthly)||1.36|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Pharmaceutical companies can trade sideways for years, and may see a spike every now and then due to positive announcements or an FDA approval update. The newest subset of the biotech industry, known as gene therapy companies, has been multiplying at an astonishing rate. As a result, they have many new stocks listed to capital markets. These companies have recently piqued the interest of investors, and analysts are weighing in. Many individuals are born with disorders for which there is no cure,
Cancer scares are dissipating from experimental treatments that insert functioning genes in patients whose damaged copies cause sickle cell, hemophilia and other congenital diseases.
AVROBIO (AVRO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.